Clinical TrialJul 6, 2026, 07:32 AM
CervoMed to Present 5 Neflamapimod Data Presentations at AAIC
AI Summary
CervoMed Inc. announced that its lead drug candidate, neflamapimod, will be featured in five presentations at the upcoming Alzheimer's Association International Conference (AAIC) from July 12-15, 2026. These presentations will highlight neflamapimod's impact on Dementia with Lewy Bodies (DLB) disease progression, neurodegeneration biomarkers, and basal forebrain atrophy, including initial clinical data for the 80mg BID dose. The company continues to seek a strategic partner for a Phase 3 DLB trial and anticipates interim biomarker data for its nfvPPA trial and first patient dosing for its EXPERTS-ALS trial in Q4 2026.
Key Highlights
- CervoMed to feature five presentations on neflamapimod at the AAIC meeting from July 12-15, 2026.
- Presentations will cover neflamapimod's impact on DLB disease progression, biomarkers, and basal forebrain atrophy.
- Includes first clinical data for neflamapimod 80mg BID dose from a Phase 2 study in Dementia with Lewy Bodies (DLB).
- Neflamapimod is an oral p38α Kinase Inhibitor targeting critical disease processes in age-related brain disorders.
- CervoMed is seeking a strategic partner to advance neflamapimod into a Phase 3 trial for DLB.
- Interim biomarker data from the Phase 2a nfvPPA trial is anticipated in Q4 2026.
- First patient dosing in the EXPERTS-ALS Phase 2a clinical trial is expected in Q4 2026.
Price Impact
More from CRVO